Medical Biochemistry& Molecular Biology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Medical Biochemistry Department, Faculty of Medicine, Suez University, Suez, Egypt.
Asian Pac J Cancer Prev. 2022 Aug 1;23(8):2735-2742. doi: 10.31557/APJCP.2022.23.8.2735.
miRNA 223 /125a and Cordon-bleu Protein Like 1 (COBLL1) are novel biomarkers that can predict prognosis and guide treatment decisions in patients with chronic lymphocytic leukemia (CLL). Also, there is a growing interest in CLL monitoring based on flow cytometry of receptor tyrosine kinase-like orphan receptor-1 (ROR-1). Objective: This study aimed to evaluate the relationship between miRNA 223 /125a and COBLL1 expressions and ROR-1 expression in patients with CLL. Also, the study evaluated the relationship between the expression of these biomarkers with tumor staging and cancer progression.
Our study included 40 patients newly diagnosed with B-CLL. In peripheral blood (PB), miRNA 223/125a and COBLL1 expressions were detected by real-time polymerase chain reaction (real-time PCR) and ROR-1 percentage was detected by flow cytometry before and after treatment. Results: High level of COBLL1 expression was statistically significantly associated with high ROR-1 percentage expression (P= 0.03). However, a high level of miRNA 223/125a expression was statistically significantly associated with low ROR-1 percentage expression (P=0.002). The sensitivity and specificity of ROR-1 as a predictor of high WBCs count after treatment were 96.6 and 81.1%, respectively. There was a statistically significant reduction of ROR-1 percentage after treatment compared to before treatment (P <0.001).
ROR-1 percentage expression can be considered a possible prognostic predictor in CLL along with miRNA 223/125a and COBLL1 expressions. This can be explained by the significant correlation between ROR-1 and the studied molecular biomarkers; miRNA 223/125a and COBLL1. In addition, there was a significantly higher ROR-1 percentage in patients with higher WBC counts. Moreover, there was a significant reduction in ROR-1 percentage after treatment.
miRNA 223/125a 和 Cordon-bleu 蛋白样 1（COBLL1）是新型生物标志物，可预测慢性淋巴细胞白血病（CLL）患者的预后并指导治疗决策。此外，基于受体酪氨酸激酶样孤儿受体-1（ROR-1）的流式细胞术监测 CLL 受到越来越多的关注。目的：本研究旨在评估 CLL 患者中 miRNA 223/125a 和 COBLL1 表达与 ROR-1 表达之间的关系。此外，还评估了这些生物标志物的表达与肿瘤分期和癌症进展之间的关系。
本研究纳入了 40 例新诊断的 B-CLL 患者。在治疗前后，通过实时聚合酶链反应（real-time PCR）检测外周血（PB）中 miRNA 223/125a 和 COBLL1 的表达，通过流式细胞术检测 ROR-1 的百分比。结果：COBLL1 高表达与 ROR-1 高百分比表达呈统计学显著相关（P=0.03）。然而，miRNA 223/125a 高水平表达与 ROR-1 低百分比表达呈统计学显著相关（P=0.002）。ROR-1 作为治疗后白细胞计数高的预测因子的灵敏度和特异性分别为 96.6%和 81.1%。与治疗前相比，治疗后 ROR-1 的百分比有统计学显著降低（P<0.001）。
ROR-1 百分比表达可与 miRNA 223/125a 和 COBLL1 表达一起作为 CLL 的潜在预后预测因子。这可以通过 ROR-1 与研究的分子生物标志物（miRNA 223/125a 和 COBLL1）之间的显著相关性来解释。此外，白细胞计数较高的患者中 ROR-1 的百分比更高。此外，治疗后 ROR-1 的百分比显著降低。
